Bravecto Spot-On For Cats 13.8-27.5 lbs (6.25-12.5 kg)

Description

Bravecto Spot-On For Cats 13.8-27.5 lbs (6.25-12.5 kg) with 500 mg fluralaner is the highest-strength variant in the Bravecto cat topical range, formulated for larger-bodied cats requiring a minimum delivered dose of 18.2 mg/lb (40 mg/kg) body weight. The 500 mg tube covers the same four-parasite spectrum as smaller variants, with protection against fleas sustained for 12 weeks and against Dermacentor variabilis ticks for 8 weeks per dose. Cats exceeding 27.5 lbs (12.5 kg) fall outside the single-tube dosing range and should receive an appropriate combination of tubes as directed by a veterinarian.

Recommended for:

Cats and kittens weighing 13.8 to 27.5 lbs (6.25 to 12.5 kg) from 6 months of age.

Indication/Coverage

For cats suffering from, or at risk from, parasitic infestations involving fleas and ticks:

• Flea treatment and prevention: Kills adult Ctenocephalides felis (cat flea) and prevents reinfestation; laboratory studies confirm over 98% reduction in live flea counts within 12 hours of application, with sustained flea control across the full 12-week dosing interval.
• Black-legged tick control: Treatment and control of Ixodes scapularis infestations; over 94% effectiveness at 48 hours post-infestation, maintained for 12 weeks post-dosing.
• Asian longhorned tick control: Treatment and control of Haemaphysalis longicornis infestations; over 94% effectiveness at 48 hours post-infestation for 12 weeks.
• American dog tick control: Treatment and control of Dermacentor variabilis infestations; over 98% effectiveness for 8 weeks post-dosing. Efficacy against this species is not maintained beyond 8 weeks; an 8-week redosing schedule applies when ongoing D. variabilis exposure is confirmed.

Key Benefits

The following properties are drawn from labeled efficacy and safety data specific to the 500 mg fluralaner formulation for cats in the 13.8 to 27.5 lb weight range:

• Large cat suitability: Approved for cats from 13.8 lbs (6.25 kg) and 6 months of age, covering the weight range of large domestic breeds including Maine Coon, Norwegian Forest Cat, and Ragdoll cats that fall outside smaller-variant dose bands.
• Systemic isoxazoline action: Fluralaner is absorbed dermally, reaches peak plasma concentration between 7 and 21 days post-application, and carries an elimination half-life of 11 to 13 days; parasites are killed when they feed on treated blood rather than through coat contact.
• Four-species ectoparasite coverage: A single 500 mg tube addresses C. felis, I. scapularis, H. longicornis, and D. variabilis concurrently, covering all primary tick species of clinical relevance across U.S. regions in one application.
• Rapid flea kill onset: In laboratory studies, 100% of fleas were eliminated within 8 hours of treatment; live flea counts were reduced by over 98% within 12 hours, including after re-infestation at any point in the 12-week dosing period.
• Extended 12-week dosing interval: One application every 12 weeks replaces the monthly spot-on schedule required by most competing flea products, reducing the frequency of physical handling for large cats that are particularly resistant to restraint.
• Flea allergy dermatitis resolution: Sustained adult flea elimination in U.S. field studies produced documented clinical improvement in erythema, papules, scales, alopecia, crusts, and excoriation associated with flea allergy dermatitis.
• Topical format for large, oral-resistant cats: Larger cats are often among the most difficult to dose orally; spot-on delivery bypasses palatability and swallowing compliance entirely, and the single application point at the base of the skull minimises restraint time.
• Cats over 27.5 lbs: The label specifies that cats exceeding 27.5 lbs should receive an appropriate combination of tubes. Consult a veterinarian to confirm the correct tube combination for cats above this upper boundary.

Caution

Hazards to Humans

Not for human use; keep out of reach of children and store in the original packaging until the moment of use to prevent accidental access. Avoid contact with skin and eyes during application; flush eyes slowly with water if exposure occurs and seek immediate medical advice if contact lenses are in place. Wash hands and any contacted skin with soap and water after handling. The product is highly flammable; keep away from heat, open flame, and ignition sources at all times.

Hazards to Domestic Animals

For topical use only; oral ingestion should be avoided. This variant is indicated for cats and kittens from 6 months of age weighing 13.8 lbs (6.25 kg) or more. Safety has not been established in breeding, pregnant, or lactating cats; veterinary assessment is required before administering to animals in these categories. Fluralaner is an isoxazoline-class compound linked to neurologic adverse reactions including tremors, ataxia, and seizures in cats, including those with no prior neurologic history. Use with caution in cats with a history of neurologic disorders, and consult a veterinarian if concurrent medications are being administered.

Possible Side Effects

Observe your cat closely for at least 48 hours after spot-on application, with particular attention after the first dose at this weight band.

The adverse reactions below are drawn from U.S. and European field studies and post-approval reporting for fluralaner:

• Application site reactions: A greasy, oily, or wet appearance at the base of the skull is routinely observed in the hours following dosing; matting, clumping, and hair spiking at the application site were recorded in safety studies at doses up to 5x the labeled maximum.
• Gastrointestinal signs: Vomiting occurred in 7.6% of fluralaner-treated cats in the U.S. field study (n=224 over 105 days); diarrhea was reported in 4.9% and decreased appetite in 3.6% of treated cats across the same observation period.
• Dermal signs: Pruritus was recorded in 5.4% of treated cats in the field study; alopecia in 4.9%, and scabs or ulcerated lesions in 2.2%. Post-approval reports also include application site erythema and localized pruritus distinct from the generalised form.
• Systemic and neurologic signs: Post-approval reports include ataxia, muscle tremors, hypersalivation, lethargy, and behavioral changes including hyperactivity, hiding, and vocalization. In a European field study, two cats from the same household developed tremors, lethargy, and anorexia within one day of dosing; both recovered within 48 to 72 hours without intervention.

If any of these signs emerge or do not resolve within 72 hours, contact a veterinarian.